FDA approves Litfulo for adults and adolescents with severe alopecia areata
Pfizer Inc. has announced that the FDA has approved Litfulo (ritlecitinib), a once-daily oral treatment, for individuals 12 years of age and older with severe alopecia areata
The approved recommended dose for Litfulo is 50 mg. It is the first and only treatment approved by the FDA for adolescents (12+) with severe alopecia areata.
“While patients may start to develop symptoms of alopecia areata at any age, most people start showing signs in their teens, twenties, or thirties,” said Dr. Brittany Craiglow, Associate Professor Adjunct – Dermatology at Yale School of Medicine. “Litfulo is a particularly important treatment option for younger patients with substantial hair loss, who often struggle with such a visible disease.”
Litfulo is a kinase inhibitor which inhibits Janus kinase 3 (JAK3) and the tyrosine kinase expressed in hepatocellular carcinoma (TEC) family of kinases.
60 mins
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.